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c-Jun N-terminal kinase (JNK) is activated by cellular stress and plays critical roles in diverse types of cell
death. However, role of JNK in -cell injury is obscure. We investigated the role for JNK in streptozotocin
(STZ)-induced-cell death. STZ induced JNK activation in insulinoma or islet cells. JNK inhibitors attenu-
ated insulinoma or islet cell death by STZ. STZ-induced JNK activation was decreased by PARP inhibitors,
suggesting that JNK activation is downstream of PARP-1. Phosphatase inhibitors induced activation of
JNK and abrogated the suppression of STZ-induced JNK activation by PARP inhibitors, suggesting that
the inhibition of phosphatases is involved in the activation of JNK by STZ. STZ induced production of
reactive oxygen species (ROS) as potential inhibitors of phosphatases, which was suppressed by PARP
inhibitors. PARP-1 siRNA attenuated insulinoma cell death and JNK activation after STZ treatment, which
was reversed by MKP (MAP kinase phosphatase)-1 siRNA. These results suggest that JNK is activated by
STZ downstream of PARP-1 through inactivation of phosphatases such as MKP, which plays important
roles in STZ-induced -cell death.
1. Introduction
Streptozotocin (STZ) is a well-known diabetogenic agent and
has been widely used to study the mechanism of pancreatic -cell
death and diabetes. STZ is a glucose analogue that is transported
into pancreatic -cells via GLUT-2 transporter system (Schnedl et
al., 1994). STZ, as an alkylating agent similar to N-methyl-N′-nitro-
N-nitrosoguanidine (MNNG) or other nitrosoureas, induces strand
breaks and methylation of genomic DNA, leading to activation
of poly(ADP-ribose) polymerase-1 (PARP-1) (LeDoux et al., 1988).
While PARP-1 activation in response to DNA breaks is amechanism
to repair damaged DNA and to maintain genomic DNA stability (de
Murcia et al., 1997; Wang et al., 1997), excessive PARP-1 activa-
tion, e.g., that after STZ treatment, could be deleterious to the cells
by depleting NAD+ through alternating formation and degradation
of poly(ADP-ribose) (PAR) (Hoorens and Pipeleers, 1999; Okamoto
and Takasawa, 2002). Indeed, PARP-1-null mice are resistant to the
development of diabetes after STZ treatment (Burkart et al., 1999b;
Pieper et al., 1999).
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However, it is still controversial whether NAD+ depletion by
PARP-1 activation is the sole mechanism of cell death by STZ
(Chiarugi, 2002). Furthermore, intracellular signaling downstream
of PARP-1 activation and the biochemical mechanism by which
nuclear damage by STZ is translated to the entire series of cell
death events in cytoplasm and mitochondria are not clearly
elucidated.
Mitogen-activated protein (MAP) kinase is a typical element
of cellular responses against extracellular stimuli. The c-Jun N-
terminal kinase (JNK) is a group of MAP kinases that is activated
by cytokines and cellular stress. While activation of MAP kinases
including JNK is essentially an adaptive process to environmen-
tal changes, excessive or prolonged activation of JNK leads to cell
death, which may represent a mechanism to remove extensively
damaged cells and to avoid futile expenditure of cellular energy.
Thus, JNK activation plays an important role in a variety of cell
death types including apoptosis and necrosis (Kamata et al., 2005;
Tournier et al., 2000).
As a cellular response against cell stress, JNK activation is likely
to occur in DNA damage and cell death by STZ. Indeed, activation
of JNK has been reported to occur when PARP-1 is activated by
an alkylating agent, MNNG (Xu et al., 2006). While these results
suggest that JNK activation could be involved in STZ-induced -
cell death, this possibility has not been systematically studied. We
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pathogenesis of both natural type 1 and type 2 diabetes (Hirosumi
et al., 2002; Jaeschke et al., 2005) is involved in the STZ-induced
-cell death.
2. Materials and methods
2.1. Cell cultures
NIT-1, insulinoma cells established from SV40 T-transgenic NOD/Lt mice, were
cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% FCS,
100U/ml penicillin, 100g/ml streptomycin, and 2mmol/l glutamine at 37 ◦C in
humidiﬁed 5% CO2/95% air.
2.2. MTT assays
Cell viability was measured using 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT; Sigma, St. Louis, MO, USA) assay as described
(Suk et al., 2001b). In some experiments, cells were pretreated with various
inhibitors such as SP600125 (Calbiochem, La Jolla, CA, USA), 3,4-dihydro-5-[4-(1-
piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ; Alexis Biochemicals, Grünberg,
Germany), nicotinamide (Sigma), okadaic acid (Sigma) or vanadate (Sigma) before
STZ treatment.
2.3. Hoechst/PI staining
To distinguish apoptotic cells from necrotic cells, double staining with 5g/l
Hoechst 33342 and 2.5g/l PI (Molecular Probes, Eugene, OR, USA) was done. Cells
with intact blue nuclei, condensed/fragmented blue nuclei, and intact pink nuclei
were considered as viable, apoptotic, and necrotic cells, respectively (Suk et al.,
2001a).
2.4. RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA,
USA). After reverse transcription using SuperScript II (Invitrogen), cDNA was
subjected to PCR ampliﬁcation employing speciﬁc primer sets (JNK1 forward,
5′-CAGAGGTCATTCTCGGCATG-3′; reverse, 5′-GGAGAGCTTCATCTACGGAG-3′; JNK2
forward, 5′-GCATTCAGCTGGTATCATTC-3′; reverse, 5′-GATGGTGTTCCTAGCTGTTC-
3′; JNK3 forward, 5′-GGTGATTCAGATGGAGCTGG-3′; reverse, 5′-CCACGTAGTTT-
CTGACTGTG-3′; PARP-1 forward, 5′-CGGAGAGGCTTTATCGAGTG-3′; reverse, 5′-
TACCCAGCTGTGGCTTCTCT-3′; MKP-1 forward, 5′-AGGACAACCACAAGGCAGAC-3′;
reverse, 5′-GGGATGGAAACAGGGAAGTT-3′).
2.5. ROS measurement
Intracellular reactive oxygen species (ROS) content was measured using ﬂuo-
rescent probes as described (Park et al., 2004). In short, cells plated in 6-well plates
were incubated with 1mol/l dihydroethidium (HE; Molecular Probes) or 1mol/l
2′ ,7′-dichloroﬂuorescein diacetate (DCFH-DA; Molecular Probes) at 37 ◦C for 20min
without light exposure. Then, the cellswereharvestedandanalyzedbyFACSanalysis
(BD Biosciences, Franklin Lakes, NJ, USA).
2.6. Western blot
After lysis of cells in a buffer (10mmol/l Tris–HCl, pH 7.5, 100mmol/l NaCl, 1%
Nonidet P-40, 1mmol/l EDTA, 1mmol/l Na3VO4, 1mmol/l NaF, 1mmol/l phenyl-
methylsulfonyl ﬂuoride and protease inhibitor cocktail), protein expression was
examined by immunoblotting using speciﬁc antibodies to phospho-JNK (Cell Signal-
ing Technology, Beverly, MA, USA), total JNK (Santa Cruz, Santa Cruz, CA, USA), PAR
(Calbiochem), PARP-1 (Cell Signaling Technology) and -actin (Abcam, Cambridge,
MA, USA) as described (Suk et al., 2001b).
2.7. siRNA experiment
siRNA for murine PARP-1 (5′-GACACAGAAUCCUAGCCGA-3′), MKP-1 (5′-
CUAGAAACUUCAUGCUUGA-3′) or an irrelevant green ﬂuorescence protein (GFP)
(Bioneer, Daejeon, Korea) was transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. The expression of PARP-1 and MKP-1 was
evaluated by RT-PCR and Western blotting as in Sections 2.4 and 2.6.
2.8. Isolation of pancreatic islets
Pancreatic isletswere isolated fromC57BL/6miceusing thepreviouslydescribed
method of collagenase digestion and Ficoll density gradient centrifugation (Suk et
al., 2001b). Then, trypsinized single islet cellswere incubated inRPMI1640medium-
10% FCS.
2.9. Statistical analysis
The results were presented as means± SEM. Student’s t-test was employed
to compare the differences between two groups. When more than two groups
were compared, statistic signiﬁcance was determined by one-way ANOVA with
Newman–Keuls post hoc test. For all statistical analyses, P values less than 0.05 were
regarded as signiﬁcant.
3. Results
3.1. JNK expression in insulinoma cell lines and primary islet cells
We ﬁrst studied whether various isoforms of JNK are expressed
in pancreatic islet cells because JNK isoforms have different expres-
sionpatternanddistinct role in response to cell stress and invarious
modes of cell death. RT-PCR analysis showed that JNK1, 2 and 3
were all expressed in NIT-1 insulinoma cells and primary islet cells
(Fig. 1a).
3.2. JNK activation by STZ
We next investigated whether JNK is activated in insulinoma
cells by STZ treatment. Immunoblotting showed that JNK was
strongly activated in insulinoma cells after 10mmol/l STZ treat-
ment for 30–120min (Fig. 1b). Persistent activation of JNK over
90min suggested that the JNK activation by STZ was a prolonged
one that could exert cell death (Tang et al., 2001). We next stud-
ied the role for JNK activation in insulinoma cell death by STZ
because JNK activation is involved in diverse types of cell death
and JNK inhibitors are able to suppress cell death in such mod-
els. SP600125, a JNK inhibitor that has been used in a wide
variety of cell death models, signiﬁcantly inhibited insulinoma
cell death by STZ treatment for 24h in a dose-dependent man-
ner, suggesting that JNK activation contributes to the death of
insulinoma cells by STZ (Fig. 1c). Type of STZ-induced cell death
suppressed by JNK inhibitors was mostly necrosis because ﬂuo-
rescent microscopy after Hoechst/PI staining showed that, while
86% of total insulinoma cells underwent necrosis characterized
by PI uptake without nuclear condensation/fragmentation after
treatment with 10mmol/l STZ, percentage of such cells was sig-
niﬁcantly decreased to 27% in the presence of SP600125 (P<0.01)
(Fig. 1d). Only a few apoptotic cells characterized by nuclear con-
densation/fragmentation without PI uptake were observed after
10mmol/l STZ treatment of NIT-1 insulinoma cells (Fig. 1d), while
apoptotic cells were well observed after treatment with lower dose
of STZ (data not shown).
3.3. JNK activation downstream of PARP-1 activation
We next studied the relationship between PARP-1 activation
that plays a crucial role in STZ-induced-cell injury and JNK activa-
tion. Treatment with PARP inhibitors such as DPQ or nicotinamide,
inhibited STZ-induced insulinoma cell death as previously reported
(Burkart et al., 1999a) (Fig. 2a). Here, we examined whether JNK
activation observed after STZ treatment of insulinoma cells could
be modulated by PARP inhibitors. DPQ inhibited STZ-induced JNK
activation in doses that suppressed PARP-1 activation and PAR pro-
duction (Fig. 2b), suggesting that JNK activation is downstream
of PARP-1 activation. Nicotinamide, another PARP inhibitor, also
inhibited STZ-induced JNK activation in NIT-1 insulinoma cells
(Fig. 2b). On the contrary, JNK inhibitor did not inhibit PARP-1
activation by STZ in doses that inhibited JNK activation (Fig. 2c),












Fig. 1. JNK activation in STZ-induced insulinoma cell death. (a) Total RNA was extracted from NIT-1 insulinoma cells (left) or primary islet cells (right). RT-PCR was done
using primer sets speciﬁc for each JNK isotype. (b) NIT-1 cells were treated with STZ (10mmol/l) or sodium citrate (Cont) for the indicated time period. Whole cell lysates
were then subjected to immunoblot analysis using antibodies against phospho-JNK and total JNK. (c) NIT-1 cells were pretreated for 1h with the indicated concentrations of
a JNK inhibitor, SP600125 (SP) and then exposed to STZ (10mmol/l). MTT assay was carried out 24h later. The data in this ﬁgure are presented as the mean± SEM of three
independent experiments. (***P<0.001 compared to NIT-1 cells treated with STZ alone) (d) Insulinoma cells were treated with STZ (10mmol/l) for 24h in the presence or
absence of SP, and apoptotic or necrotic cells were counted after Hoechst/PI double staining on a ﬂuorescent microscope (400×) (left bars, apoptosis; right bars, necrosis). The
data in this ﬁgure are presented as the mean± SEM of three independent experiments. (**P<0.01 compared to NIT-1 cells treated with STZ alone).
Fig. 2. Effect of PARP inhibitors on JNK activation by STZ. (a) NIT-1 cells were pretreated for 1h with the indicated concentrations of PARP inhibitor, DPQ or nicotinamide, and
then exposed to STZ (10mmol/l). MTT assay was carried out 24h later. The data in this ﬁgure are presented as the mean± SEM of three independent experiments. (***P<0.001
compared to NIT-1 cells treated with STZ alone) (b) NIT-1 cells were pretreated for 1h with the indicated concentrations of DPQ or nicotinamide, and then treated with STZ
(10mmol/l) for 1h. Total cell lysates were subjected to immunoblotting using anti-phospho-JNK, -total JNK or -PAR antibody. (c) NIT-1 cells were pretreated for 1h with the











Fig. 3. Effect of PARP inhibitors on ROS production by STZ. After pretreatment with the indicated concentration of DPQ or nicotinamide (NA) for 1h, NIT-1 cells were
treated with STZ (10mmol/l) for 3h. Then, FACS analysis after staining with HE and DCFH-DA was done to measure intracellular superoxide and hydrogen peroxide levels,
respectively. Numbers in the boxes indicate the percentage of stained cells.
3.4. Role of ROS in JNK activation by STZ
Next, we investigated the mechanism of JNK activation by STZ
downstream of PARP-1. We studied whether ROS are produced
because PARP-1 activation has been reported to mediate ROS pro-
duction (Gille et al., 2002) and ROS are able to activate JNK by
inhibiting phosphatases (Owens and Keyse, 2007). FACS analysis
afterHE andDCFH-DA staining that detect predominantly superox-
Fig. 4. Effect of phosphatase inhibitors on the suppression of STZ-induced JNK activation and cell death by PAPR inhibitors. (a) After pretreatment of NIT-1 cells with DPQ
(50mol/l) in the presence or absence of phosphatase inhibitors (okadaic acid (OA) or vanadate) for 1h, cells were treated with STZ (10mmol/l). After 1h of incubation, total
cell lysates were subjected to immunoblotting using antibodies against phospho-JNK and total JNK. (b) After pretreatment of NIT-1 cells with DPQ in the presence or absence
of phosphatase inhibitors (OA or vanadate) for 1h, cells were treated with STZ (10mmol/l). After 24h of incubation, MTT was done. The data in this ﬁgure are presented












ide anion and hydrogen peroxide, respectively (Kim and Lee, 2005),
showed that ROS are produced after STZ treatment of insulinoma
cells (Fig. 3). ROS produced by STZ were suppressed by DPQ or
nicotinamide (Fig. 3), consistentwith a previous paper showing the
role for PARP-1 in ROS production during cellular injury (Virag et
al., 1998). Because previous papers showed the role of phosphatase
inhibition by ROS in JNK activation (Kamata et al., 2005; Owens and
Keyse, 2007), we studied whether phosphatases inhibitors could
affect the activation of JNK and viability of insulinoma cells. Phos-
phatase inhibitors such as okadaic acid or vanadate abrogated the
suppression of STZ-induced JNK activation by DPQ (Fig. 4a, lanes
3–5 from the left for okadaic acid and vanadate), suggesting that
JNK activation by STZ involves phosphatases downstream of PARP-
1 activation. Phosphatase inhibitors alone without STZ treatment
also induced activation of JNK in insulinoma cells (Fig. 4a, lane 6
from the left for okadaic acid and lane 1 from the left for vanadate),
supporting the role of basal phosphatase activity in the modulation
of JNK activity. These results suggest that JNK is activated by STZ as
a downstream event of PARP-1 activation through inactivation of
phosphatases, which plays an important role in the death of insuli-
noma cells by STZ. Consistent with the prolonged activation of JNK
by phosphatase inhibitors, okadaic acid or vanadate induced insuli-
noma cell death (Fig. 4b, bars 3–5 from the left for okadaic acid and
vanadate). They also inhibited suppression of STZ-induced insuli-
noma cell death by DPQ (Fig. 4b, bars 6–9 from the left for okadaic
acidandvanadate), supporting that inhibitionofphosphatasesafter
STZ treatment of insulinoma cells contributes to the prolonged JNK
activation and ensuing cell death.
3.5. Effect of PARP-1 and MKP-1 siRNA
Because these results were obtained using chemical inhibitors
that could have nonspeciﬁc effects, we validated our results
employing siRNA strategy. Transfection of NIT-1 cells with PARP-1
siRNA that was effective in downregulating PARP-1 mRNA expres-
sion (Fig. 5a), signiﬁcantly inhibited NIT-1 cell death by 10mM STZ
compared to control GFP siRNA transfection (P<0.001) (Fig. 5b).
PARP-1 siRNA transfection also decreased JNK activation after STZ
treatment (Fig. 5c), supporting that JNK activation downstream
of PARP-1 is involved in insulinoma cell death by STZ. We also
employed siRNA targeting MAP kinase phosphatase (MKP) since
MKPs directly dephosphorylate MAP kinase such as JNK or p38
among phosphatases (Kamata et al., 2005; Sakon et al., 2003). We
chose MKP-1 that has a critical and nonredundant role in JNK
dephosphorylation among MKPs as the target (Wu and Bennett,
2005). Combined transfection of MKP-1 siRNA that suppressed
MKP-1 expression (Fig. 5a), abrogated PARP-1 siRNA effect both
Fig. 5. Effect of PARP-1 or MKP-1 siRNA on STZ-induced JNK activation and cell
death. (a) Forty-eight hours after transfection of NIT-1 cellswith PARP-1,MKP-1 and
GFP siRNA, the expression of PARP-1 and MKP-1 mRNA was determined by RT-PCR.
(b) Seventy-two hours after transfection, NIT-1 cells were treated with 10mmol/l
STZ for 24h. Cell survival/death was evaluated by MTT assay. The data in this ﬁgure
are presented as the mean± SEM of three independent experiments. (**P<0.01 and
***P<0.001) (c) Seventy-two hours after transfection, NIT-1 cells were treated with
10mmol/l STZ for 1h. Total cell lysates were subjected to immunoblotting using
antibodies against PARP-1, phospho-JNK and -actin.
on the cell death and JNK activation (Fig. 5b and c), suggesting
that the effects of chemical inhibitors of phosphatase are most
likely due to the inhibition of MKP rather than their nonspeciﬁc
effects.
Fig. 6. JNK activation in primary islet cell death by STZ. (a) Pancreatic islet cells isolated from C57BL/6 mice were treated with STZ (10mmol/l) for 1h with or without DPQ
(50mol/l) pretreatment for 1h. Cell lysates were subjected to immunoblotting using anti-phospho-JNK, -total JNK, -PAR or -actin antibody. (b) Primary islet cells were
pretreated with JNK inhibitor, SP600125 (SP) for 1h and then exposed to STZ or vehicle. After 24h, MTT assay was done as in Fig. 1c. (***P<0.001 compared to primary islet











3.6. Suppression of islet cell death by JNK inhibitors
We ﬁnally tested whether JNK activation by STZ plays a role
in the death of primary islet cells as well as that of insulinoma
cells. STZ treatmentof primarymurine islet cells fromC57BL/6mice
for 1h induced a strong activation of JNK, which was inhibited by
pretreatment with DPQ in doses that inhibited PARP-1 activation
(Fig. 6a), which is similar to the treatment of insulinoma cells with
STZ and supports that JNK activation is downstreamof PARP-1 acti-
vation. Similar to the case of NIT-1 insulinoma cells, STZ treatment
for 24h exerted cytotoxicity on islet cells which were signiﬁcantly
inhibited by SP600125 (Fig. 6b). These results indicated that JNK
activation plays an important role in STZ-induced death not only of
insulinoma cells but also of primary islet cells.
4. Discussion
In this investigation to study the role of JNK activation in STZ-
mediated -cell injury, we observed that JNK activation occurs
downstream of PARP-1 and contributes to the -cell death by
STZ. Detail mechanism of JNK activation downstream of PARP-1
activation after STZ treatment of -cells is not clearly elucidated.
ROS production by PARP-1 activation appears to contribute to the
JNK activation after STZ treatment of -cells because ROS were
produced in response to STZ and ROS are able to activate JNK
by inhibiting phosphatases. MKPs that directly dephosphorylate
JNK or other phosphatases that target the upstream of JNK may
be involved in STZ-induced JNK activation (Kamata et al., 2005;
Sakon et al., 2003). These results implicating the role for ROS in
STZ-induced JNK activation probably through inhibition of phos-
phatases are consistent with previous papers showing the role for
PARP-1 as an ampliﬁer of ROS production in the course of cell
death (Virag et al., 1998) and our data showing that phosphatase
inhibitors not only induced JNK activation themselves but also
abrogated the suppression of STZ-induced JNK activation by PARP
inhibitors. Our data using chemical inhibitors of PARP or phos-
phatases do not appear to be due to their nonspeciﬁc effects since
PARP-1 or MKP-1 siRNA has similar effects on JNK activation and
insulinoma cell death. In contrast, a recent paper reported a role for
MEKK-1, a MAPK3 kinase upstream of JNK rather than MKP in -
cell death by ROS or STZ (Mokhtari et al., 2008).While these reports
implicated a role for ROS in -cell injury by STZ, ROS may not be
the only mediators inducing JNK activation in STZ-mediated -cell
injury because several ROS scavengers did not inhibit JNK activa-
tion after treatment of insulinoma cells with STZ (data not shown).
For instance, PAR that is produced abundantly after STZ treatment
has been reported to contribute to cell death (Yu et al., 2006).
While the main function of PARP-1 activation would be to
maintain genomic DNA stability (de Murcia et al., 1997; Wang et
al., 1997), new functions of PARP-1 are being recognized. PARP-1
appears to be critically involved in the regulation of transcrip-
tional factors such as NF-B, p53, AP-1 (Chiarugi, 2002) and HIF-1
(Martin-Oliva et al., 2006) since activation of such transcriptional
factors is impaired inPARP-1-null cells or byPARP inhibitors. In glial
cells, activation of transcriptional factors and production of inﬂam-
matorymediatorswere abrogatedby targeteddisruptionofPARP-1,
while such ﬁndings appear to be tissue-speciﬁc (Ha, 2004). Abroga-
tion of JNK activation in PARP-1-null mouse embryonic ﬁbroblasts
(Xu et al., 2006) or by PARP inhibitors in our study may also be
related to the role of PARP-1 in the activation of transcriptional fac-
tors as JNK is critically involved in the activation of c-Jun, a subunit
of AP-1.
Our results demonstrated a role of JNKactivation in STZ-induced
-cell death and diabetes. JNK plays an important role in the patho-
genesis of diabetes. In type 2 diabetes, JNK activation is critically
involved in insulin resistance (Hirosumi et al., 2002; Solinas et al.,
2006). In-cells of type2diabetesmodels, JNKactivationdecreases
insulin production from them (Kaneto et al., 2002) and induces
lipotoxicity (Martinez et al., 2008). While mechanistically differ-
ent, JNK is also involved in type 1 diabetes. JNK has been reported
to play a role in the differentiation of Th1/Th2 cells and cytokine-
mediated -cell injury (Bonny et al., 2001; Jaeschke et al., 2005).
A recent paper reported that the incidence of diabetes after multi-
ple low-dose STZ treatment, an artiﬁcial model of type 1 diabetes,
was lower in JNK1-null mice, which was attributed to decreased
cytokine production in those mice (Fukuda et al., 2008).
In conclusion, these results suggest that PARP-1 plays impor-
tant roles in the activation of various transcriptional factors or MAP
kinases such as JNK and production of inﬂammatory mediators or
ROS in addition to its classical role in the protection of genomic
DNA. In the course of such intracellular processes, JNK appears to
be activated downstream of PARP-1 activation which contributes
to the execution of cell death by STZ.
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